Lexington, United States
Genezen, founded in 2014 in Indianapolis, IN, is a prominent player in the gene therapy CDMO industry. With a slogan of "Bringing Therapies to Life", the company leverages over a decade of experience to support the global cell and gene therapy manufacturing market.
Genezen specializes in diverse vector modalities, including AAV, lentiviral, and retroviral vectors, offering tailored partnership models that cater to organizations of all sizes. This flexibility has made them a go-to partner for both early-stage biotech ventures and established pharmaceutical leaders. Their state-of-the-art facility in Lexington, MA, boasts multiple global regulatory approvals, facilitating the manufacture of commercial viral vector-based products.
Recently, Genezen secured an $18.50M Growth Equity VC investment from Ampersand Capital Partners, signaling strong confidence in its strategic direction and capacity for scaling operations. This investment will likely bolster its capabilities in cGMP manufacturing at the Indianapolis site, which is currently supporting clinical trial initiatives.
